Softwr

Healthcare · head to head

Paige vs UpToDate

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite
UpToDate logo

UpToDate

Healthcare

Evidence-based clinical decision support for healthcare providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; UpToDate upToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.
  • They diverge on capability: Paige covers Paige Prostate Detect, UpToDate covers Clinical Evidence.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and UpToDate actually diverge.

Attributes where Paige and UpToDate differ
AttributePaigeUpToDate
Pricing modelquotesubscription
PlatformsWeb, Cloud, On-premiseWeb, Mobile
FoundedUnknown1992

Identical on both: starting price (On request), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in UpToDate

  • Clinical Evidence
  • Drug Information
  • Calculators
  • Medical Images
  • Videos
  • CME Credits
  • EHR Systems
  • Mobile

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot UpToDate
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot UpToDate
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot UpToDate
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot UpToDate

UpToDate

  • Patient Carenot Paige
  • Medical Recordsnot Paige
  • Practice Managementnot Paige
  • Telehealthnot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

UpToDate

  • UpToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

UpToDate

On request

No published plan breakdown. See the UpToDate review.

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Choose UpToDate if

  • You need clinical evidence.
  • You work on Web, Mobile.
  • You also want drug information.
UpToDate review

Questions people ask

Is Paige or UpToDate better?
Neither clearly leads. Paige starts at On request and UpToDate at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or UpToDate?
Paige starts at On request and UpToDate at On request.
Does Paige or UpToDate run on more platforms?
Paige runs on Web, Cloud, On-premise. UpToDate runs on Web, Mobile.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what UpToDate is typically brought in for.
What can Paige do that UpToDate cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications. UpToDate covers Clinical Evidence, Drug Information, Calculators, Medical Images.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Paige

More on UpToDate

Keep looking

Other head to heads